Active Projects

This is the jumping-off point for all TLS drug development projects.

From here, you'll be able to access Project Portfolio for each drug candidate, where you'll have the opportunity to provide high-level input via TLS Protocol Builders, our crowdsourcing survey tool to develop clinical protocols . Each project has its own Protocol Builder that asks specific questions relating to each compound’s indication and trial design. Click on a project heading for more information.

Indication Finder:  A Repurposing Hunt  We invite you to participate in a unique exercise.  The U.S. National Center for Advancing Translational Sciences (NCATS) has posted a list of 58 compounds that are available for repurposing studies.  We need your help to determine if some of these compounds might help patients in other indications and be good candidates for the open innovation approach to drug development.  Intrigued? Cick here to find out more!


Kiacta in Sarcoidosis

Why Study Kiacta in Sarcoidosis?

TLS has begun a collaboration with Auven Therapeutics to develop Kiacta in sarcoidosis. Kiacta is a compound developed by Auven Therapeutics for AA amyloidosis and sarcoidosis. TLS is assisting Auven on the sarcoidosis aspect of the program.

  • Sarcoidosis is a disease of unknown origin with autoimmune features that causes granulomatous inflammation. It often affects the lungs and can cause pulmonary scarring.
     
  • The current treatments for pulmonary sarcoidosis include corticosteroids and immunomodulatory medications, which may cause severe side effects.
     
  • Kiacta is a molecule specifically designed to inhibit amyloid deposition into tissues. It presents the opportunity for a safer treatment than corticosteroids.
Protocol Builder ResultsStart Protocol Builder Now!
Telemedicine Acceptance in IBD
Protocol Builder Input Period Has Closed. Thank You for Participating.

Why study telemedicine acceptance in IBD?

Transparency Life Sciences, in collaboration with Genentech, a member of the Roche Group, is conducting a pilot study in patients with inflammatory bowel disease.

  • The primary objective of this pilot study is to evaluate the effectiveness and ease-of-use of telemonitoring technology and techniques in assessing standard clinical endpoints in IBD.

  • We are focused on new methods to include patients’ local gastroenterologists in the development and execution of a clinical trial.

  • We are also investigating the role of dietary intervention in a trial in IBD.

  • We are interested in learning which symptoms are most important to IBD patients, and how they think those symptoms can be monitored at home.

Protocol Builder Results
Metformin in Prostate Cancer
Protocol Builder Input Period Has Closed. Thank You for Participating.

Why metformin in prostate cancer?

  • Approximately 20-30% of men treated with surgery or radiation will develop recurrence of their prostate cancer, which most commonly manifests as a rising PSA level in the blood, commonly referred to as a “biochemical recurrence”.
    • This can occur many years before any evidence of cancer spread can be detected on imaging tests such as CT scans or bone scans.
       
  • Standard therapy for prostate cancer that has spread is treatment to lower the testosterone level in the body (aka, androgen deprivation therapy or ‘hormonal therapy’). This treatment has unfavorable side effects. Whether such treatment should be started for patients with a rising PSA, without any evidence of detectable spread on cancer on scans, is controversial.
     
  • Metformin is an oral drug used to treat diabetes. Several lines of evidence point to a potential for metformin to be effective in the treatment of prostate cancer.
     
  • Epidemiologic studies of patients with prostate cancer and diabetes have shown that patients taking metformin may have a lower likelihood of recurrence of the prostate cancer after surgery or radiation, and they may have a lower likelihood of dying of prostate cancer, when compared to patients not taking the drug.
     
  • Metformin can be tested for efficacy in patients with prostate cancer who experience a recurrence, as manifested by a rising PSA blood level after surgery or radiation. If clinical studies confirm its utility, it may provide an alternative for patients with prostate cancer, delaying or preventing the need for androgen deprivation therapy.

Please take part in designing an innovative clinical study of metformin in patients with recurrent prostate cancer, as manifested by a rising PSA blood test (biochemical recurrence), after surgery or radiation. 

Protocol Builder Results
Pioglitazone in Parkinson's Disease

Why pioglitazone in Parkinson’s disease?

  • Parkinson’s disease (PD) is a chronic neurodegenerative condition with no cure. In the US alone, it is diagnosed in more than 50,000 new patients every year.

  • PD is caused by the death of dopaminergic neurons in the brain, which are involved in the control of movement.

  • Current treatments can provide symptomatic relief in the early stages of the disease but all have undesired side effects, some serious, and do not halt disease progression.

  • Drugs like pioglitazone (glitazones; PPAR activators) have been used in millions of patients to treat type 2 diabetes. At least three lines of evidence point to a potential for pioglitazone to be effective in the treatment of Parkinson's Disease:

    • Inhibition of neuroinflammation involving reactive microglia

    • Activation of genes controlling cellular bioenergetics

    • Inhibition of MAO-B

  • Pioglitazone can be tested for efficacy in patients with PD; if clinical studies confirm its utility it might provide a real alternative for thousands suffering with PD

Please take part in designing an innovative clinical study of pioglitazone in PD.

Protocol Builder ResultsStart Protocol Builder Now!
Lisinopril in Multiple Sclerosis
Protocol Complete—Available for Comment

Why lisinopril in multiple sclerosis (MS)?

  • Multiple sclerosis is a disease of the immune system which acts against patients' own nervous system cells.  Available therapies modulate the immune system

  • Treatments are modestly effective, but all have undesired side effects, some serious

  • Lisinopril (an ACE inhibitor) is a drug that has been used in millions of patients worldwide for years as a safe and effective treatment for hypertension

  • Lisinopril has been tested in well-established animal models of MS. Results provide compelling evidence that ACE inhibitors modulate immune response

  • TLS is testing lisinopril as an adjunctive therapy in patients with MS; if clinical studies confirm its utility, as an inexpensive solution it might provide a real alternative for thousands suffering with MS

 Please take part in designing an innovative clinical study of lisinopril in MS.

Protocol Builder Results
Low-Dose Naltrexone ("LDN") in Crohn's
The Protocol Builder has been suspended because TLS was unable to secure rights to the project.

Why investigate LDN in Crohn's disease?

  • Crohn's disease remains poorly treated in many patients and it is amenable to being studied clinically using telemonitoring methods. Anecdotal evidence of LDN's efficacy in Crohn's Disease has been reinforced with compelling data from a recently-completed randomized placebo-controlled trial.